Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4917523 as adjunctive therapy in major depressive disorder with inadequate antidepressant response
jRCT2080221839Phase 1
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of basimglurant in major depressive disorder (MDD) (3 arms), sponsored by Roche.
02
Drugs
basimglurant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221839.